DiaMedica Diabetes Treatment Gets Positive Results

DiaMedica‘s Phase I/II trial of DM199 in Type 2 diabetic patients reached its primary clinical endpoints of demonstrating its safety, tolerability and sustained pharmacokinetic (PK) properties, while also suggesting an insulin sensitization mechanism of action for Type 2 diabetes.

The randomized, double-blinded, placebo-controlled study enrolled 10 Type 2 diabetic patients. The patients were dosed with either DM199 at three single ascending dose levels or placebo. DM199 was well-tolerated at all three dose levels by the diabetic patients with no dose limiting side effects. In addition, results from secondary endpoints of the clinical trial assessing glucose control were consistent with an insulin sensitization mechanism of action. Insulin sensitizers lower a patient’s blood sugar levels by increasing the body’s response to insulin over time. Full results of the study will be published as part of the overall Phase I/II clinical trial.

In a separate study to the ongoing Phase I/II clinical trial, DiaMedica recently completed a Phase I PK study in 14 healthy volunteers demonstrated DM199 has an extended half-life (time required to reduce concentration of drug in body by one-half) confirming earlier PK results. DM199 also had long half-life and similar PK profile in Type 2 diabetic patients.